CopyMark Law Group
4.9/5
Drawing for F FIERCE PHARMA

USPTO serial 98923826

F FIERCE PHARMA

Reviewed by CopyMark Law Group

Reg. 8074264Status 700Registered
Filing date
Status date
Registration date
Dec 23, 2025
Examiner
BERGER, MAGDALENA
Law office
FILE REPOSITORY (FRANCONIA)

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with F FIERCE PHARMA?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Trademark Monitoring
(312) 319-4460
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Start a new application
(312) 319-4460

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Deborah J. Peckham

Deborah J. Peckham Barclay Damon LLP160 Federal Street, Suite 1001Boston, MA 02110United States

Goods and services

ClassDescriptionStatusFirst use
035Conducting, arranging, promoting and organizing trade shows, business expos and buyer events for business purposes in the fields of pharmaceuticals, drug policy, drug development, cell and gene therapy, drug manufacturing and drug regulations; providing public policy information in the field of drugsACTIVEJun 5, 2020
041Arranging and conducting in-person educational forums, educational meetings, conferences, and conventions in the fields of pharmaceuticals, drug policy, drug development, cell and gene therapy, drug manufacturing and drug regulations; educational services, namely, arranging and conducting educational conferences, seminars and workshops in the fields of pharmaceuticals, drug policy, drug development, cell and gene therapy, drug manufacturing and drug regulations; providing information and news in the fields of pharmaceuticals, drug policy, drug development, cell and gene therapy, drug manufacturing and drug regulations; providing online, non-downloadable newsletters in the fields of pharmaceuticals, drug development, cell and gene therapy, drug manufacturing and drug regulations; conducting of business conferences in the field of pharmaceuticals, drug policy, drug development, cell and gene therapy, drug manufacturing and drug regulationsACTIVEJun 5, 2020
042Providing medical and scientific research information and news in the fields of pharmaceuticals, drug development, cell and gene therapy, and drug manufacturingACTIVEJun 5, 2020

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Dec 23, 2025NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Dec 23, 2025R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Nov 4, 2025NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Nov 4, 2025PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Oct 29, 2025NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Oct 1, 2025CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Sep 22, 2025XAECEXAMINER'S AMENDMENT ENTERED—
Sep 22, 2025GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Sep 22, 2025GNEAEXAMINERS AMENDMENT E-MAILED—
Sep 22, 2025CNEAEXAMINERS AMENDMENT -WRITTEN—
Sep 11, 2025TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Sep 11, 2025CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Sep 11, 2025TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jun 11, 2025GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 11, 2025GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 11, 2025CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 5, 2025DOCKASSIGNED TO EXAMINER—
May 27, 2025MDSMNOTICE OF DESIGN SEARCH CODE E-MAILED—
May 27, 2025NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Dec 26, 2024NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance